Clinical Trial Update: Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes a study evaluating cladribine plus pegylated interferon alfa-2a for systemic mastocytosis in Phase 2 and Phase 3, with the curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• Cladribine (cladribine)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Hospital Virgen de la Salud | Conditions: Systemic Mastocytosis | Phase 2, Phase 3 | Status: UNKNOWN